MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Avatud

SektorTervishoid

3.1 -0.64

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.09

Max

3.16

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Aktsiakasum	-0.21
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+295.19% upside

Turustatistika
By TradingEconomics
Turukapital	196M 743M
Eelmine avamishind	3.74
Eelmine sulgemishind	3.1

Uudiste sentiment

By Acuity

60%

40%

323 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. dets 2025, 22:20 UTC

Suurimad hinnamuutused turgudel

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31. dets 2025, 17:31 UTC

Suurimad hinnamuutused turgudel

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31. dets 2025, 16:30 UTC

Suurimad hinnamuutused turgudel

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31. dets 2025, 15:19 UTC

Suurimad hinnamuutused turgudel

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31. dets 2025, 15:17 UTC

Suurimad hinnamuutused turgudel

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31. dets 2025, 14:37 UTC

Suurimad hinnamuutused turgudel

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. dets 2025, 21:13 UTC

Omandamised, ülevõtmised, äriostud

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31. dets 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31. dets 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31. dets 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31. dets 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31. dets 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31. dets 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31. dets 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31. dets 2025, 17:16 UTC

Suurimad hinnamuutused turgudel

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31. dets 2025, 17:00 UTC

Omandamised, ülevõtmised, äriostud

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31. dets 2025, 15:57 UTC

Omandamised, ülevõtmised, äriostud

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31. dets 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31. dets 2025, 15:02 UTC

Suurimad hinnamuutused turgudel

Nike Shares Rise After CEO Hill Buys $1M of Shares

31. dets 2025, 14:40 UTC

Omandamised, ülevõtmised, äriostud

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31. dets 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31. dets 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31. dets 2025, 13:01 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31. dets 2025, 11:10 UTC

Market Talk

Copper Remains in Touching Distance of Record Highs -- Market Talk

31. dets 2025, 10:46 UTC

Market Talk

Euro on Track For Strong Annual Performance -- Market Talk

31. dets 2025, 10:25 UTC

Market Talk

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31. dets 2025, 10:23 UTC

Market Talk

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31. dets 2025, 09:33 UTC

Market Talk

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

295.19% tõus

12 kuu keskmine prognoos

Keskmine 12.33 USD 295.19%

Kõrge 15 USD

Madal 10 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

323 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.